CA3304242A1 - Formulations pharmaceutiques comprenant du 5-meo-dmt et leurs utilisations thérapeutiques - Google Patents

Formulations pharmaceutiques comprenant du 5-meo-dmt et leurs utilisations thérapeutiques

Info

Publication number
CA3304242A1
CA3304242A1 CA3304242A CA3304242A CA3304242A1 CA 3304242 A1 CA3304242 A1 CA 3304242A1 CA 3304242 A CA3304242 A CA 3304242A CA 3304242 A CA3304242 A CA 3304242A CA 3304242 A1 CA3304242 A1 CA 3304242A1
Authority
CA
Canada
Prior art keywords
dmt
meo
pharmaceutical formulations
therapeutic uses
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3304242A
Other languages
English (en)
Inventor
Dario Dornbierer
Davor Kosanic
Milan Scheidegger
Robin VON ROTZ
Daniel CLAUSSEN
Original Assignee
Reconnect Labs Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reconnect Labs Ag filed Critical Reconnect Labs Ag
Publication of CA3304242A1 publication Critical patent/CA3304242A1/fr
Pending legal-status Critical Current

Links

CA3304242A 2023-10-23 2024-10-23 Formulations pharmaceutiques comprenant du 5-meo-dmt et leurs utilisations thérapeutiques Pending CA3304242A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23205374.4 2023-10-23
EP24175819.2 2024-05-14

Publications (1)

Publication Number Publication Date
CA3304242A1 true CA3304242A1 (fr) 2025-05-01

Family

ID=

Similar Documents

Publication Publication Date Title
EP4255903A4 (fr) Hétéroaryle-acétylènes, compositions pharmaceutiques de ceux-ci et leurs applications thérapeutiques
CA3304242A1 (fr) Formulations pharmaceutiques comprenant du 5-meo-dmt et leurs utilisations thérapeutiques
CA3266804A1 (fr) Composition pharmaceutique et son utilisation
CA3262492A1 (fr) Formulations comprenant g-csf et leurs utilisations
HK40131600A (en) Pharmaceutical formulations and uses thereof
EP4364735A4 (fr) Composition pharmaceutique et son utilisation
AU2024902868A0 (en) Pharmaceutical Formulations and Uses Thereof
HK40089929A (zh) 药物制剂及其用途
CA3300004A1 (fr) Formulations pharmaceutiques de bictégravir et de lénacapavir
HK40122888A (en) Pharmaceutical formulations of bictegravir and lenacapavir
CA3298458A1 (fr) Formulations pharmaceutiques pour inhalation et leurs utilisations
ES3064824T3 (en) Pharmaceutical formulations of bictegravir and lenacapavir
HK40113484A (en) Pharmaceutical preparation and application thereof
HK40130783A (zh) 药物组合及其用途
CA3304458A1 (fr) Combinaison pharmaceutique et utilisation
AU2024368057A1 (en) Pharmaceutical composition and use thereof
CA3301973A1 (fr) Composition pharmaceutique et son utilisation
CA3298413A1 (fr) Composition pharmaceutique et utilisation associée
CA3278393A1 (fr) Composition pharmaceutique et utilisation associée
HK40120642A (en) Therapeutic compounds, formulations, and use thereof
CA3262078A1 (fr) Composés thérapeutiques, formulations et leur utilisation
CA3304568A1 (fr) Compositions pharmaceutiques contenant du maralixibat et leurs utilisations
CA3305049A1 (fr) Conjugués ligand-médicament cytotoxique et leurs utilisations pharmaceutiques
CA3270902A1 (fr) Combinaisons pharmaceutiques et leurs utilisations
HK40124257A (en) Pharmaceutical combinations and uses thereof